Lactate dehydrogenase-to-albumin ratio: A superior inflammatory marker for predicting contrast-associated acute kidney injury after percutaneous coronary intervention
- PMID: 38402549
- PMCID: PMC10823551
- DOI: 10.1002/clc.24219
Lactate dehydrogenase-to-albumin ratio: A superior inflammatory marker for predicting contrast-associated acute kidney injury after percutaneous coronary intervention
Abstract
Purpose: Inflammation is commonly considered a mechanism underlying contrast-associated acute kidney injury (CA-AKI). This study aimed to explore the predictive capability of the novel inflammatory marker lactate dehydrogenase-to-albumin ratio (LAR) for CA-AKI following percutaneous coronary intervention (PCI), and further compare it with other common inflammatory biomarkers.
Methods: This study enrolled 5,435 patients undergoing elective PCI. The primary outcome was CA-AKI, and the secondary outcome was all-cause mortality. All patients were grouped into three groups based on the LAR tertiles.
Results: Three hundred fifteen patients (5.8%) experienced CA-AKI during hospitalization. The fully adjusted logistic regression suggested a significant increase in the risk of CA-AKI in LAR Tertile 3 (odds ratio [OR]: 2.51, 95% confidence interval [CI]: 1.68-3.83, p < .001) and Tertile 2 (OR: 2.11, 95% CI: 1.42-3.20, p < .001) compared to Tertile 1. Additionally, receiver operating characteristic (ROC) analysis demonstrated that LAR exhibited significantly superior predictive capability for CA-AKI compared to other inflammatory biomarkers. Regarding the secondary outcome, multivariate COX regression analysis showed a positive correlation between elevated LAR levels and all-cause mortality.
Conclusion: In patients undergoing elective PCI, LAR was significantly independently associated with CA-AKI, and it stood out as the optimal inflammatory biomarker for predicting CA-AKI.
Keywords: all-cause mortality; contrast-associated acute kidney injury; lactate dehydrogenase-to-albumin ratio; percutaneous coronary intervention.
© 2024 The Authors. Clinical Cardiology published by Wiley Periodicals LLC.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
References
-
- Valle JA, McCoy LA, Maddox TM, et al. Longitudinal risk of adverse events in patients with acute kidney injury after percutaneous coronary intervention: insights from The National cardiovascular data registry. Circ Cardiovas Intervent. 2017;10(4):e004439. - PubMed
-
- Weisbord SD, Palevsky PM, Kaufman JS, et al. Contrast‐associated acute kidney injury and serious adverse outcomes following angiography. J Am Coll Cardiol. 2020;75(11):1311‐1320. - PubMed
-
- Mehran R, Dangas GD, Weisbord SD. Contrast‐Associated acute kidney injury. N Engl J Med. 2019;380(22):2146‐2155. - PubMed
-
- Gurm HS, Hyder SN. Reducing risk of contrast‐associated acute kidney injury. JACC. 2023;16(12):1514‐1516. - PubMed
MeSH terms
Substances
Grants and funding
- The Cardiovascular Disease Clinical and Research Platform (National Regional Medical Center)
- 81873495/National Natural Science Foundation of China General Program
- 82171569/National Natural Science Foundation of China General Program
- The National Key Clinical Specialty Construction Project of China (Cardiovascular Medicine 2021)
- The Heart Failure Center Research Foundation of Fujian Provincial Hospital (supported by the Fujian Provincial Department of Finance)
LinkOut - more resources
Full Text Sources
Miscellaneous
